论文部分内容阅读
本文用免疫组化法对15例乳腺癌做了多药耐药基因产物P17。及谷航计肽S一转移酶（GST。）以及雌孕激素受体（ER，PR）的检测。浸润性导管瘤14例，粘液腺癌1例。检测结果雌孕激素受体共同表达率为667％（IO门5），巳？。过度表达为“7（10／15）．GSTx过度表达为553％（8／15）。ER、PR表达与肿瘤的分化程度有关，即分化好的乳腺癌标记率较高，提示预后较好。结果表明多数乳腺癌表达雌孕激素受体，提示对内分泌治疗有效。P；0，GST，不仅为乳腺癌标记物，而且也提示了多数乳腺癌对亲脂类及烷化剂类化疗药可能具有耐药性。因此时过度表达的乳腺癌临床上应慎用此类化疗药。
In this paper, 15 cases of breast cancer were treated with immunohistochemical method P17. And glutamine peptide S-transferase (GST.) As well as estrogen and progesterone receptor (ER, PR) detection. Invasive ductal tumors in 14 cases, 1 case of mucinous adenocarcinoma. The co-expression rate of estrogen and progesterone receptors was found to be 667% (Iomen 5). . Overexpression was "7(10/15). GSTx overexpression was 553% (8/15). ER, PR expression was related to the degree of tumor differentiation, that is, the marked rate of well-differentiated breast cancer was higher, suggesting a better prognosis. The results showed that most breast cancers express estrogen and progesterone receptors, suggesting that they are effective for endocrine therapy.P;0, GST, not only breast cancer markers, but also suggest that most breast cancers may be to lipophilic and alkylating agents. With drug resistance, such over-expressed breast cancer should be used with caution in clinical practice.